Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria
Tfh 对新型候选疫苗的反应以及对小儿恶性疟疾的保护
基本信息
- 批准号:9750040
- 负责人:
- 金额:$ 66.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-11 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:2 year oldAcuteAdultAgeAlgorithmsAntibodiesAntibody ResponseAntigensAntimalarialsAreaBLR1 geneBiological AssayBirthBlocking AntibodiesCXCR3 geneChildChildhoodClinicalDataDefectDependenceDiseaseEpitopesErythrocytesFalciparum MalariaFlow CytometryFormulationFundingGenerationsHelper-Inducer T-LymphocyteHepatocyteHumanImmuneImmunoglobulin Class SwitchingImmunoglobulin GImmunoglobulin Somatic HypermutationIncidenceIndividualInfectionKenyaKineticsKnowledgeLengthLongitudinal cohort studyMHC Class II GenesMalariaMalaria VaccinesMapsMeasuresMemory B-LymphocyteMerozoite Surface Protein 1MethodsParasitemiaParasitesPeptidesPeripheral Blood Mononuclear CellPlanetsPlasmaPlasma CellsPlasmodium falciparumProductionProteinsProteomePublishingRecombinant ProteinsReportingResearchResistanceResistance to infectionRoleSLEB2 geneSamplingScienceSeasonsSentinelStructure of germinal center of lymph nodeT-Lymphocyte EpitopesT-Lymphocyte SubsetsTanzaniaTimeVaccinationVaccine AntigenVaccinesWorkagedbasecohortcytokinedensityearly childhoodepidemiologic dataexperienceimmunogenicityinterleukin-21malaria infectionmalenovelnovel vaccinesprospectiveresponsescreeningtransmission processvaccine candidatevaccine development
项目摘要
ABSTRACT
Our overall aim is to advance PfSEA-1 as a vaccine candidate for pediatric falciparum malaria by identifying
broadly reactive, PfSEA-1 specific T follicular helper (Tfh) epitopes, which are critical for long-lived antibody
responses.
In previous R01 funded studies, We discovered Schizont Egress Antigen-1 (PfSEA-1), a 244-kDa parasite
antigen that is the target of antibodies which arrest parasites at the schizont stage. Active vaccination with
rPbSEA-1 results in a 3-fold reduction in parasitemia and a 2 fold longer survival time after challenge with P.
berghei ANKA parasites (P = 0.001). Children in our Tanzanian birth cohort (N=785) experienced a
dramatically increased incidence of severe malaria during periods with undetectable anti-PfSEA-1 antibody
levels (45 cases/23,806 child weeks) compared to periods with detectable antibody levels (0 cases/1,688 child
weeks; adjusted OR 4.4; Type III fixed effects P < 0.01). In our cohort of Kenyan males (12-35 yrs old, N= 138),
individuals with detectable anti-PfSEA-1 IgG antibodies had 50% decreased parasite density compared to
individuals with undetectable anti-PfSEA-1 IgG antibodies (P < 0.04) over an 18-week high transmission
season. This work has culminated in a comprehensive, full length Research Article in Science 1.
A major obstacle to malaria vaccine development is the generation of high-titer functional antibodies with the
induction of long-lived plasma and memory B-cells. In the past 10 yrs, Tfh cells have been recognized as
essential for somatic hypermutation, isotype switching, germinal center formation, long lived plasma cell
formation as well as memory B cell formation 2. Intriguingly, in the only report of Tfh cells in human malaria
infection, inefficient activation of the CXCR3- subset of Tfh cells was observed during acute malaria infections
in children, and this defect may be responsible for the poor anti-malarial antibody responses seen in early
childhood 3. Based on the known function of Tfh cells and their role in generating protective antibody
responses to vaccine antigens 4, 5, identifying Tfh epitopes is essential for malaria vaccine optimization.
In the current application, we propose to map Tfh stimulating, MHC Class II T cell epitopes in PfSEA-1 using
both recombinant protein as well as overlapping peptide approaches. We will initially identify all possible
peptide specific epitopes in a cross-sectional sample of semi-immune adults. We will then relate antibody,
cytokine, and T-cell subset responses to these epitopes with resistance to infection in a longitudinal cohort
study conducted in 2-7 yr old children living in a holoendemic region of western Kenya.
The deliverables from this study will be a list of validated T cell epitopes within the novel egress blocking
vaccine candidate PfSEA-1 and a comprehensive, prospective analysis of the relationship between antibody,
cytokine and T-cell subset responses to these epitopes and resistance to infection with P. falciparum. These
data will allow us to enhance the immunogenicity of second generation rPfSEA-1A based vaccines by including
broadly reactive T cell epitopes from the flanking regions, or increasing the copy number of T-cell epitopes
within the aa 810-1083 region. In addition, these results will significantly increase our understanding of the role
and kinetics of Tfh cell responses during pediatric malaria infections.
摘要
我们的总体目标是通过鉴定PfSEA-1,
广泛反应性的PfSEA-1特异性T滤泡辅助(Tfh)表位,其对于长寿命抗体至关重要
应答
在之前的R 01资助的研究中,我们发现了裂殖体出口抗原-1(PfSEA-1),一种244-kDa的寄生虫
抗体的目标抗原,抗体能将寄生虫捕获在前体阶段。主动接种,
rPbSEA-1导致寄生虫血症减少3倍,并且在用P.
伯氏ANKA寄生虫(P = 0.001)。我们坦桑尼亚出生队列中的儿童(N=785)经历了
在检测不到抗PfSEA-1抗体期间,严重疟疾的发病率急剧增加
与可检测抗体水平的时期(0例/1 688名儿童)相比,
3周;调整OR 4.4; III型固定效应P < 0.01)。在我们的肯尼亚男性队列(12-35岁,N= 138)中,
具有可检测的抗PfSEA-1 IgG抗体的个体与具有可检测的抗PfSEA-1 IgG抗体的个体相比,
在18周的高传播中,未检测到抗PfSEA-1 IgG抗体的个体(P < 0.04)
赛季这项工作最终在《科学1》上发表了一篇全面的、完整的研究文章。
疟疾疫苗开发的一个主要障碍是用免疫球蛋白产生高滴度的功能性抗体。
诱导长寿命血浆和记忆B细胞。在过去的10年里,Tfh细胞被认为是
对体细胞超变、同种型转换、生发中心形成、长寿浆细胞至关重要
形成以及存储器B单元形成2.有趣的是,在人类疟疾中Tfh细胞的唯一报告中,
感染,在急性疟疾感染期间观察到Tfh细胞的CXCR 3亚群的无效激活
这种缺陷可能是造成早期抗疟抗体反应不良的原因。
童年3.基于Tfh细胞的已知功能及其在产生保护性抗体中的作用,
针对疫苗抗原4、5的应答,鉴定Tfh表位对于疟疾疫苗优化是必要的。
在本申请中,我们提出使用以下方法来定位PfSEA-1中的Tfh刺激性MHC II类T细胞表位:
重组蛋白以及重叠肽方法。我们将初步确定所有可能的
肽特异性表位在半免疫成人的横截面样品。然后我们将抗体,
细胞因子和T细胞亚群对这些表位的反应,在纵向队列中对感染具有抗性
在生活在肯尼亚西部完全流行地区的2-7岁儿童中进行的研究。
本研究的可交付成果将是新的出口阻断中经验证的T细胞表位列表。
候选疫苗PfSEA-1和抗体之间关系的全面、前瞻性分析,
细胞因子和T细胞亚群对这些表位的应答以及对恶性疟原虫感染的抗性。这些
数据将使我们能够通过以下方法增强第二代基于rPfSEA-1A的疫苗的免疫原性
广泛反应性T细胞表位从侧翼区,或增加T细胞表位的拷贝数
在AA 810-1083区域内。此外,这些结果将大大增加我们对角色的理解
和小儿疟疾感染期间Tfh细胞反应的动力学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan D. Kurtis其他文献
Acquired von Willebrand disease: Management of labor and delivery with intravenous dexamethasone, continuous factor concentrate, and immunoglobulin infusion
- DOI:
10.1016/j.ajog.2004.09.020 - 发表时间:
2005-06-01 - 期刊:
- 影响因子:
- 作者:
Heather S. Lipkind;Jonathan D. Kurtis;Raymond Powrie;Marshall W. Carpenter - 通讯作者:
Marshall W. Carpenter
Jonathan D. Kurtis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan D. Kurtis', 18)}}的其他基金
Identifying the targets of protective immunity to severe falciparum malaria
确定严重恶性疟疾的保护性免疫目标
- 批准号:
10893666 - 财政年份:2023
- 资助金额:
$ 66.41万 - 项目类别:
Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria
Tfh 对新型候选疫苗的反应以及对小儿恶性疟疾的保护
- 批准号:
9977935 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
One Health Vaccine Development for Bovine and Human Schistosomiasis
一种针对牛和人类血吸虫病的健康疫苗的开发
- 批准号:
10019231 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria
Tfh 对新型候选疫苗的反应以及对小儿恶性疟疾的保护
- 批准号:
10227778 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
One Health Vaccine Development for Bovine and Human Schistosomiasis
一种针对牛和人类血吸虫病的健康疫苗的开发
- 批准号:
10189672 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
One Health Vaccine Development for Bovine and Human Schistosomiasis
一种针对牛和人类血吸虫病的健康疫苗的开发
- 批准号:
10430376 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
PfSEA-1 based vaccines for falciparum malaria
基于 PfSEA-1 的恶性疟疾疫苗
- 批准号:
9330056 - 财政年份:2014
- 资助金额:
$ 66.41万 - 项目类别:
PfSEA-1 based vaccines for falciparum malaria
基于 PfSEA-1 的恶性疟疾疫苗
- 批准号:
8817017 - 财政年份:2014
- 资助金额:
$ 66.41万 - 项目类别:
相似海外基金
Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
- 批准号:
2885806 - 财政年份:2023
- 资助金额:
$ 66.41万 - 项目类别:
Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
- 批准号:
10772386 - 财政年份:2023
- 资助金额:
$ 66.41万 - 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
474619 - 财政年份:2022
- 资助金额:
$ 66.41万 - 项目类别:
Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
- 批准号:
485965 - 财政年份:2022
- 资助金额:
$ 66.41万 - 项目类别:
Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
466358 - 财政年份:2022
- 资助金额:
$ 66.41万 - 项目类别:
Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
- 批准号:
402040 - 财政年份:2019
- 资助金额:
$ 66.41万 - 项目类别:
Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 66.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
- 批准号:
377313 - 财政年份:2017
- 资助金额:
$ 66.41万 - 项目类别:
Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
- 批准号:
9315111 - 财政年份:2016
- 资助金额:
$ 66.41万 - 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
- 批准号:
8734273 - 财政年份:2013
- 资助金额:
$ 66.41万 - 项目类别: